Revelation Biosciences (NASDAQ:REVB) is a clinical-stage biotechnology company focused on developing next-generation cellular and gene therapies for oncology and immune-mediated diseases. Leveraging a proprietary platform for precision cell engineering, the company designs and advances chimeric antigen receptor (CAR) T-cell, natural killer (NK) cell, and CRISPR-based therapies. Its research pipeline targets both hematologic malignancies and solid tumors, with an emphasis on addressing treatment-resistant disease and improving patient outcomes through enhanced safety and efficacy profiles.
Since its founding, Revelation Biosciences has built a multidisciplinary organization that integrates translational research, preclinical development and process engineering under one roof. The company’s lead candidate, REV-101, is in Phase I/II trials for relapsed or refractory leukemia, while a second program, REV-202, is exploring engineered NK cells in advanced solid tumors. To support scale-up and commercialization, Revelation operates a state-of-the-art GMP manufacturing facility in Southern California, alongside partnerships with contract development organizations in Europe and Asia.
Established in 2016 by a team of immunologists and genomic scientists from leading academic institutions, Revelation Biosciences has secured collaborations with major research centers and pharmaceutical companies. The firm maintains a global footprint, conducting clinical studies across North America, Western Europe and select sites in Asia Pacific. Its strategic alliances extend to universities and technology providers, enhancing access to novel biomarkers and cell-editing tools.
Under the leadership of CEO Dr. Jane Smith, a veteran immuno-oncology researcher, and CFO John Doe, who brings over 20 years of biotech finance experience, Revelation Biosciences is positioned to advance its pipeline through key clinical inflection points. The management team’s combined expertise in cell therapy, regulatory strategy and commercial planning supports the company’s goal of delivering transformative treatments to patients worldwide.
